AstraZeneca’s Oral PCSK9 Inhibitor AZD0780 Demonstrates Significant LDL-C Reduction in Phase 1 Trial

1. AZD0780 Phase 1 Trial Results: AstraZeneca's oral PCSK9 inhibitor, AZD0780, has shown significant reductions in low-density lipoprotein cholesterol (LDL-C) in a phase 1 trial when administered on top of statin therapy.
2. LDL-C Reduction: The trial demonstrated a statistically significant reduction in LDL-C levels, with a decrease of approximately 65% at day 14 compared to baseline levels.
3. Safety and Tolerability: AZD0780 was well tolerated in the trial, with no major safety concerns reported.
4. Hypercholesterolemia Treatment: The development of oral PCSK9 inhibitors like AZD0780 aims to provide an alternative to injectable PCSK9 inhibitors for treating hypercholesterolemia, a major risk factor for atherosclerotic cardiovascular disease (ASCVD).
5. Competition with Merck: AstraZeneca's AZD0780 is competing with Merck's MK-0616, another investigational oral PCSK9 inhibitor that has shown significant LDL-C reduction in a phase 2b study.